Johnson Chemical Pharmaceutical Works Bilan de santé

Santé financière contrôle des critères 5/6

Johnson Chemical Pharmaceutical Works possède un total de capitaux propres de NT$1.7B et une dette totale de NT$149.7M, ce qui porte son ratio d'endettement à 8.9%. Son actif total et son passif total sont NT$1.9B et de NT$261.5M. L'EBIT de Johnson Chemical Pharmaceutical Works est NT$96.7M ce qui fait que son ratio de couverture des intérêts -9.5. Elle dispose de liquidités et de placements à court terme de NT$1.1B.

Informations clés

8.9%

Ratio d'endettement

NT$149.73m

Dette

Ratio de couverture des intérêts	-9.5x
Argent liquide	NT$1.05b
Fonds propres	NT$1.68b
Total du passif	NT$261.50m
Total des actifs	NT$1.95b

Mises à jour récentes de la santé financière

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Recent updates

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Mar 25

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

Feb 01

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Jan 12

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Dec 25

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Dec 07

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4747 ( NT$1.3B ) dépassent ses passifs à court terme ( NT$171.8M ).

Passif à long terme: Les actifs à court terme de 4747 ( NT$1.3B ) dépassent ses passifs à long terme ( NT$89.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4747 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4747 est passé de 0% à 8.9% au cours des 5 dernières années.

Couverture de la dette: La dette de 4747 est bien couverte par le flux de trésorerie opérationnel ( 55.6% ).

Couverture des intérêts: 4747 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Johnson Chemical Pharmaceutical Works Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.46 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.75 in 2Q 2023)

Now 20% overvalued

Upcoming dividend of NT$1.50 per share

First quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.74 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$2.24 (vs NT$2.16 in FY 2022)

New minor risk - Market cap size

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 24, 2024

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: NT$0.45 (vs NT$0.64 in 3Q 2022)

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.48 in 2Q 2022)

New minor risk - Market cap size

Investor sentiment improves as stock rises 26%

Upcoming dividend of NT$2.00 per share at 2.5% yield

Investor sentiment improves as stock rises 17%

First quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.42 in 1Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: NT$2.16 (vs NT$1.64 in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

No independent directors

Third quarter 2022 earnings released: EPS: NT$0.64 (vs NT$0.44 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.48 (vs NT$0.43 in 2Q 2021)

Upcoming dividend of NT$1.45 per share

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.35 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: NT$1.64 (vs NT$2.12 in FY 2020)

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 26, 2022

Third quarter 2021 earnings released: EPS NT$0.44 (vs NT$0.47 in 3Q 2020)

Upcoming dividend of NT$1.92 per share

First quarter 2021 earnings released: EPS NT$0.35 (vs NT$0.61 in 1Q 2020)

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Full year 2020 earnings released: EPS NT$2.12 (vs NT$2.15 in FY 2019)

New 90-day high: NT$37.65

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 17, 2021

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

New 90-day low: NT$36.80

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Third quarter 2020 earnings released: EPS NT$0.47

New 90-day low - NT$37.55

New 90-day low - NT$38.10

First half earnings released

New 90-day low - NT$39.00

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines